{"entity":{"id":"future-oncology","kind":"journal","name":"Future oncology","aka":["Future Oncol"],"tldr":"A high-frequency clinical oncology journal formerly from Future Medicine and now published by Taylor & Francis. It carries trial protocols, reviews and original research and is read by clinical oncologists and industry researchers.","summary":"Future Oncology is published by Taylor & Francis (Informa UK). The NLM Catalog records that it began in 2005 in London with Future Medicine Ltd, moved to Taylor & Francis in 2024, increased from thirty-six issues a year (2019 to 2021) to forty issues a year from 2022, and is indexed in MEDLINE with content deposited in PubMed Central. Crossref lists Informa UK (Taylor & Francis) as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/ifon"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101256629"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/ifon","issn":"1479-6694","scope":"clinical oncology","founded":2005,"matchNames":["Future Oncol","Future oncology","Future Oncology"]},"route":"/journals/future-oncology/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"person":[{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/"},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/"},{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/"}],"paper":[{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/"}]}}